NCT00028587 arm group e6f00f5eac162b8f44d2ea767c23413f [clinicaltrials_resource:NCT00028587/arm-group/e6f00f5eac162b8f44d2ea767c23413f]
bortezomib [clinicaltrials_resource:260b470c249aaaa705da1e01af2ffd36]paclitaxel [clinicaltrials_resource:44b61d21ae873928531f89c167bd3f90]laboratory biomarker analysis [clinicaltrials_resource:5baeebb2338c48f79e25042fe1e91735]carboplatin [clinicaltrials_resource:92f102b79f68715544afdbb2bec6c49b]PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00028587]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00028587 arm group e6f00f5eac162b8f44d2ea767c23413f [clinicaltrials_resource:NCT00028587/arm-group/e6f00f5eac162b8f44d2ea767c23413f]
Bio2RDF identifier
NCT00028587/arm-group/e6f00f5eac162b8f44d2ea767c23413f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... f00f5eac162b8f44d2ea767c23413f
description [clinicaltrials_vocabulary:description]
Patients receive bortezomib IV ...... in IV over 30 minutes on day 2
identifier
clinicaltrials_resource:NCT00028587/arm-group/e6f00f5eac162b8f44d2ea767c23413f
title
NCT00028587 arm group e6f00f5eac162b8f44d2ea767c23413f
@en
type
label
NCT00028587 arm group e6f00f5e ...... 00f5eac162b8f44d2ea767c23413f]
@en